Aryl Hydrocarbon Receptor – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)- Pipeline Review, H2 2019’, provides in depth analysis on Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Gastrointestinal, Metabolic Disorders and Genetic Disorders under development targeting Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)

– The report reviews Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics and enlists all their major and minor projects

– The report assesses Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Actavalon Inc

Active Biotech AB

Ampio Pharmaceuticals Inc

AnTolRx Inc

Bayer AG

Dermavant Sciences Inc

Hercules Pharmaceuticals BV

Hutchison MediPharma Ltd

Ikena Oncology Inc

JAGUAHR Therapeutics Pte Ltd

Magenta Therapeutics Inc

Nippon Kayaku Co Ltd

Pfizer Inc

Phenex Pharmaceuticals AG

Shenogen Pharma Group Ltd

Welichem Biotech Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Overview

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Companies Involved in Therapeutics Development

Hercules Pharmaceuticals BV

Ideaya Biosciences Inc

Kyn Therapeutics Inc

Nippon Kayaku Co Ltd

Shenogen Pharma Group Ltd

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Drug Profiles

Biologic to Agonize Aryl Hydrocarbon Receptor for Inflammatory Bowel Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Agonize Aryl Hydrocarbon Receptor for Myasthenia Gravis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cinnabarinic acid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Multiple Sclerosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Rheumatoid Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Aryl Hydrocarbon Receptor for Type 1 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HP-163 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITE Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-150460 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize AhR for Type 1 Diabetes and Graft Versus Host Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Aryl Hydrocarbon Receptor for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Aryl Hydrocarbon Receptor for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNG-162 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Dormant Products

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Product Development Milestones

Featured News & Press Releases

Nov 02, 2015: Hercules Receives €3.5 Million EUROSTARS Grant for Further Development of a New Drug for Triple Negative Breast Cancer

Sep 15, 2015: Icaritin Enters Fast Track Review for NDA

Sep 18, 2014: Icaritin Ph I Result Presents at 2014 CSCO

Jun 13, 2013: Shenogen Pharma Group: Icaritin Phase II advisory meeting held in Beijing

Jun 07, 2013: Icaritin Phase I data presented at 2013 ASCO Annual Meeting: June 3rd, 2013

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Actavalon Inc, H2 2019

Pipeline by Active Biotech AB, H2 2019

Pipeline by Ampio Pharmaceuticals Inc, H2 2019

Pipeline by AnTolRx Inc, H2 2019

Pipeline by Bayer AG, H2 2019

Pipeline by Dermavant Sciences Inc, H2 2019

Pipeline by Hercules Pharmaceuticals BV, H2 2019

Pipeline by Hutchison MediPharma Ltd, H2 2019

Pipeline by Ikena Oncology Inc, H2 2019

Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2019

Pipeline by Magenta Therapeutics Inc, H2 2019

Pipeline by Nippon Kayaku Co Ltd, H2 2019

Pipeline by Pfizer Inc, H2 2019

Pipeline by Phenex Pharmaceuticals AG, H2 2019

Pipeline by Shenogen Pharma Group Ltd, H2 2019

Pipeline by Welichem Biotech Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports